Key Market Indicators
Sales of Portuguese antihypertensive medicines are projected to dip by 2.3% annually over the next five years, from $3.4 million in 2021 to $2.9 million in 2026. Since 2005, demand has declined by a modest 0.5% annually. Portugal ranks 21st in the world for antihypertensive medicine sales. Slovenia leads the way with $3.4 million, followed by Italy, Spain and Australia.
